APA (7th ed.) Citation

JS, H., Y, M., S, J., M, W., C, H., M, P., . . . JS, W. (2026). Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: An open-label, single-centre, phase 1 study. The Lancet. Haematology, 13(2), e74. https://doi.org/10.1016/S2352-3026(25)00323-0

Chicago Style (17th ed.) Citation

JS, Heitmann, et al. "Personalised Multipeptide-based T-cell Activator for Chronic Lymphocytic Leukaemia: An Open-label, Single-centre, Phase 1 Study." The Lancet. Haematology 13, no. 2 (2026): e74. https://doi.org/10.1016/S2352-3026(25)00323-0.

MLA (9th ed.) Citation

JS, Heitmann, et al. "Personalised Multipeptide-based T-cell Activator for Chronic Lymphocytic Leukaemia: An Open-label, Single-centre, Phase 1 Study." The Lancet. Haematology, vol. 13, no. 2, 2026, p. e74, https://doi.org/10.1016/S2352-3026(25)00323-0.